When clinical IHC results were used for subgrouping, more actionable genes (1.8, p < 0.0001) and called variants (9.4, p = 0.004) were observed for ER−/HER2+ breast cancer (Table 4). This evidence concerns the gene ESR1 and breast carcinoma.